DK1583558T3 - Designede deimmuniserede monoklonale antistoffer til beskyttelse mod udsættelse for HIV og behandling af HIV-infektion - Google Patents

Designede deimmuniserede monoklonale antistoffer til beskyttelse mod udsættelse for HIV og behandling af HIV-infektion

Info

Publication number
DK1583558T3
DK1583558T3 DK03786626.6T DK03786626T DK1583558T3 DK 1583558 T3 DK1583558 T3 DK 1583558T3 DK 03786626 T DK03786626 T DK 03786626T DK 1583558 T3 DK1583558 T3 DK 1583558T3
Authority
DK
Denmark
Prior art keywords
antibodies
mab
clone
hiv
recombinant genes
Prior art date
Application number
DK03786626.6T
Other languages
English (en)
Inventor
Shugene Lynn
Chang Yi Wang
Original Assignee
United Biomedical Inc
United Biomedical Asia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc, United Biomedical Asia filed Critical United Biomedical Inc
Application granted granted Critical
Publication of DK1583558T3 publication Critical patent/DK1583558T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03786626.6T 2003-01-15 2003-11-10 Designede deimmuniserede monoklonale antistoffer til beskyttelse mod udsættelse for HIV og behandling af HIV-infektion DK1583558T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/342,959 US7501494B2 (en) 2003-01-15 2003-01-15 Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
PCT/US2003/035758 WO2004064724A2 (en) 2003-01-15 2003-11-10 Designed deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection

Publications (1)

Publication Number Publication Date
DK1583558T3 true DK1583558T3 (da) 2011-06-27

Family

ID=32711841

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03786626.6T DK1583558T3 (da) 2003-01-15 2003-11-10 Designede deimmuniserede monoklonale antistoffer til beskyttelse mod udsættelse for HIV og behandling af HIV-infektion

Country Status (12)

Country Link
US (2) US7501494B2 (da)
EP (1) EP1583558B1 (da)
CN (4) CN101293930A (da)
AT (1) ATE501172T1 (da)
AU (1) AU2003295440B2 (da)
CA (2) CA2648056C (da)
DE (1) DE60336343D1 (da)
DK (1) DK1583558T3 (da)
ES (1) ES2362874T3 (da)
HK (1) HK1088212A1 (da)
TW (2) TWI325429B (da)
WO (1) WO2004064724A2 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
JP5259392B2 (ja) * 2005-05-31 2013-08-07 ウォーソー・オーソペディック・インコーポレーテッド 疼痛を治療するための組成物および方法
CN102027016A (zh) * 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
RU2540018C2 (ru) * 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
KR20100135257A (ko) * 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
US20090005320A1 (en) * 2008-09-02 2009-01-01 Bruce Kneller Compositions comprising amino acid bicarbonate and methods of use thereof
CN102215867B (zh) * 2008-09-29 2017-04-19 生物测试股份公司 疾病治疗用组合物
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
KR101962476B1 (ko) 2009-07-03 2019-03-26 아비펩 피티와이 리미티트 면역성 접합체 및 그 제조방법
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2516462B1 (en) 2009-12-23 2015-05-06 Avipep Pty Ltd Immuno-conjugates and methods for producing them
US20120177567A1 (en) * 2010-08-11 2012-07-12 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Methods of Treating Pediatric Acute Lymphoblastic Leukemia with an Anti-CD22 Immunotoxin
WO2012113348A1 (zh) * 2011-02-25 2012-08-30 厦门大学 抗cd4蛋白的单克隆抗体及其活性片段及用途
EP2686016B1 (en) 2011-03-14 2019-05-01 Cellmid Limited Antibody recognizing n-domain of midkine
EP3103810A3 (en) 2011-04-21 2017-03-08 Garvan Institute of Medical Research Modified variable domain molecules and methods for producing and using them
US9193793B2 (en) 2011-06-13 2015-11-24 Csl Limited Antibodies against G-CSFR and uses thereof
CN104114187A (zh) * 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
CN105209057B (zh) * 2013-03-15 2020-03-27 美国卫生和人力服务部 稳定的人单cd4结构域和融合蛋白
BR112017005134A2 (pt) * 2014-09-16 2017-12-12 Ubi Ip Holdings tratamento e cura funcional de infecção por hiv por anticorpos monoclonais para inibição de entrada de hiv competitiva mediada por cd
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
US11820807B2 (en) 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
CN106267406B (zh) * 2016-07-01 2019-02-01 翁炳焕 艾滋病血液净化器
BR112019002734A2 (pt) 2016-08-13 2019-05-14 Ubi Ip Holdings tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart
EP3446710A1 (en) * 2017-08-25 2019-02-27 Glenmark Pharmaceuticals S.A. Methods of inactivating viral contaminants
AU2018377856A1 (en) 2017-11-29 2020-05-21 Csl Limited Method of treating or preventing ischemia-reperfusion injury
CN113683688B (zh) * 2021-07-23 2023-06-23 无锡傲锐东源生物科技有限公司 抗人类免疫缺陷病毒ⅰ型p24抗原（hiv-1 p24）兔单克隆抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
JPH06125783A (ja) 1991-12-28 1994-05-10 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ抗体およびその調製方法
AU688880B2 (en) 1994-03-08 1998-03-19 Ludwig Institute For Cancer Research Recombinant humanized anti-FB5 antibodies
US5961976A (en) * 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
JP3231262B2 (ja) 1996-06-05 2001-11-19 株式会社ビー・エム・エル ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
JPH10155489A (ja) 1996-11-27 1998-06-16 Asahi Chem Ind Co Ltd 組換え抗体及びそれをコードする核酸
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
CN1307640A (zh) 1998-05-25 2001-08-08 旭化成株式会社 细胞分离装置和分离方法

Also Published As

Publication number Publication date
CN100546652C (zh) 2009-10-07
AU2003295440A1 (en) 2004-08-13
CN101294159A (zh) 2008-10-29
WO2004064724A2 (en) 2004-08-05
CN101255195A (zh) 2008-09-03
DE60336343D1 (de) 2011-04-21
EP1583558B1 (en) 2011-03-09
CA2648056C (en) 2016-01-05
TWI423984B (zh) 2014-01-21
TW200418879A (en) 2004-10-01
CN1738646A (zh) 2006-02-22
US20090060914A1 (en) 2009-03-05
TWI325429B (en) 2010-06-01
CN101293930A (zh) 2008-10-29
AU2003295440B2 (en) 2010-04-01
CA2512040C (en) 2010-06-01
EP1583558A2 (en) 2005-10-12
CA2648056A1 (en) 2004-08-05
HK1088212A1 (en) 2006-11-03
ATE501172T1 (de) 2011-03-15
CN101294159B (zh) 2013-03-27
CA2512040A1 (en) 2004-08-05
CN101255195B (zh) 2013-05-15
TW200930728A (en) 2009-07-16
US7501494B2 (en) 2009-03-10
EP1583558A4 (en) 2007-02-28
US20040137000A1 (en) 2004-07-15
WO2004064724A3 (en) 2004-11-25
US7872110B2 (en) 2011-01-18
ES2362874T3 (es) 2011-07-14

Similar Documents

Publication Publication Date Title
HK1088212A1 (en) Designed deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection
JP6681327B2 (ja) 抗ｐｄ−１抗体およびその応用
HRP20180027T1 (hr) Protutijela za neutraliziranje virusa ljudske imunodeficijencije (hiv)
US10865253B2 (en) Rodent bispecific heterodimeric proteins
RU2021133819A (ru) Анти-lag-3 антитела
JP2013538057A5 (da)
JP2016533763A5 (ja) ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物
JP2015533853A5 (da)
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2013545455A5 (da)
WO2007103469A3 (en) Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
RU2012136234A (ru) Антагонистические антитела против рецептора il-7 и способы
RU2019128192A (ru) Антитело к epha4
US10501534B2 (en) Anti-malarial compositions
JP2022517441A (ja) Ｂｔｌａ抗体
RU2008138541A (ru) Способы разрушения клеток с использованием эффекторных функций анти-epha4 антител
RU2012122203A (ru) Композиции и способы для лечения восполительных нарушений
Wongsaroj et al. Modern approaches to incompatible kidney transplantation
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
JP2016518333A5 (da)
CA2256306A1 (en) Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
JP2019517813A5 (da)
EP4165080A2 (en) Btla antibodies
RU2020134360A (ru) Антитела, связывающие PD-1, и пути их применение
RU2020132497A (ru) Связывающиеся с pd-1 антитела и способы их применения